BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Mol Metab. 2017;6:1360-1370. [PMID: 29107284 DOI: 10.1016/j.molmet.2017.09.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Nevzorova YA, Boyer-diaz Z, Cubero FJ, Gracia-sancho J. Animal models for liver disease – A practical approach for translational research. Journal of Hepatology 2020;73:423-40. [DOI: 10.1016/j.jhep.2020.04.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
2 Fan Y, Ding W, Zhang C, Fu L, Xu D, Chen X. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. International Immunopharmacology 2019;77:105911. [DOI: 10.1016/j.intimp.2019.105911] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhu N, Huang S, Zhang Q, Zhao Z, Qu H, Ning M, Leng Y, Liu J. Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid. Metabolites 2021;11:374. [PMID: 34200685 DOI: 10.3390/metabo11060374] [Reference Citation Analysis]
4 Santiago P, Scheinberg AR, Levy C. Cholestatic liver diseases: new targets, new therapies. Therap Adv Gastroenterol. 2018;11:1756284818787400. [PMID: 30159035 DOI: 10.1177/1756284818787400] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
5 Hernandez ED, Zheng L, Kim Y, Fang B, Liu B, Valdez RA, Dietrich WF, Rucker PV, Chianelli D, Schmeits J, Bao D, Zoll J, Dubois C, Federe GC, Chen L, Joseph SB, Klickstein LB, Walker J, Molteni V, McNamara P, Meeusen S, Tully DC, Badman MK, Xu J, Laffitte B. Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. Hepatol Commun. 2019;3:1085-1097. [PMID: 31388629 DOI: 10.1002/hep4.1368] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
6 Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 195-210 [PMID: 29375205 DOI: 10.3748/wjg.v24.i2.195] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
7 Ghadieh HE, Muturi HT, Najjar SM. Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism. J Diabetes Treat 2017;2017. [PMID: 29431170 DOI: 10.29011/2574.7568.000033] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Li J, Liu M, Li Y, Sun DD, Shu Z, Tan Q, Guo S, Xie R, Gao L, Ru H, Zang Y, Liu H, Li J, Zhou Y. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 2020;63:12748-72. [PMID: 32991173 DOI: 10.1021/acs.jmedchem.0c01065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216-1228. [PMID: 31419514 DOI: 10.1016/j.jhep.2019.08.005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 34.3] [Reference Citation Analysis]
10 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
11 Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines 2021;9:353. [PMID: 33808404 DOI: 10.3390/biomedicines9040353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Sci Rep 2019;9:9046. [PMID: 31227742 DOI: 10.1038/s41598-019-45178-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
13 Tølbøl KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Schönberger T, Gillum MP, Hansen HH, Vrang N, Jelsing J, Feigh M, Broermann A. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Dig Dis Sci 2019;64:1238-56. [PMID: 30511198 DOI: 10.1007/s10620-018-5395-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
14 Ichimura-Shimizu M, Omagari K, Yamashita M, Tsuneyama K. Development of a novel mouse model of diet-induced nonalcoholic steatohepatitis-related progressive bridging fibrosis. Biosci Biotechnol Biochem 2021;85:941-7. [PMID: 33620426 DOI: 10.1093/bbb/zbaa107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hansen HH, Ægidius HM, Oró D, Evers SS, Heebøll S, Eriksen PL, Thomsen KL, Bengtsson A, Veidal SS, Feigh M, Suppli MP, Knop FK, Grønbæk H, Miranda D, Trevaskis JL, Vrang N, Jelsing J, Rigbolt KTG. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020;20:210. [PMID: 32631250 DOI: 10.1186/s12876-020-01356-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019;30:72-130. [PMID: 31767182 DOI: 10.1016/j.molmet.2019.09.010] [Cited by in Crossref: 212] [Cited by in F6Publishing: 204] [Article Influence: 70.7] [Reference Citation Analysis]
17 Valdecantos MP, Ruiz L, Pardo V, Castro-Sanchez L, García-Monzón C, Lanzón B, Rupérez J, Barbas C, Naylor J, Trevaskis JL, Grimsby J, Rondinone CM, Valverde ÁM. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. Sci Rep 2018;8:16461. [PMID: 30405191 DOI: 10.1038/s41598-018-33949-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Radhakrishnan S, Ke JY, Pellizzon MA. Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models. Curr Dev Nutr 2020;4:nzaa078. [PMID: 32494762 DOI: 10.1093/cdn/nzaa078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Feng R, Ma LJ, Wang M, Liu C, Yang R, Su H, Yang Y, Wan JB. Oxidation of fish oil exacerbates alcoholic liver disease by enhancing intestinal dysbiosis in mice. Commun Biol 2020;3:481. [PMID: 32879433 DOI: 10.1038/s42003-020-01213-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Radhakrishnan S, Yeung SF, Ke JY, Antunes MM, Pellizzon MA. Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models. Curr Dev Nutr 2021;5:nzab138. [PMID: 34993389 DOI: 10.1093/cdn/nzab138] [Reference Citation Analysis]
21 Donkers JM, Roscam Abbing RLP, van de Graaf SFJ. Developments in bile salt based therapies: A critical overview. Biochem Pharmacol 2019;161:1-13. [PMID: 30582898 DOI: 10.1016/j.bcp.2018.12.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
22 Ströbel S, Kostadinova R, Fiaschetti-Egli K, Rupp J, Bieri M, Pawlowska A, Busler D, Hofstetter T, Sanchez K, Grepper S, Thoma E. A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. Sci Rep 2021;11:22765. [PMID: 34815444 DOI: 10.1038/s41598-021-01951-7] [Reference Citation Analysis]
23 Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:F1000 Faculty Rev-921. [PMID: 30002817 DOI: 10.12688/f1000research.14841.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
24 Li Y, Lu LG. Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases. J Clin Transl Hepatol 2018;6:425-30. [PMID: 30637221 DOI: 10.14218/JCTH.2018.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Helmstädter M, Schmidt J, Kaiser A, Weizel L, Proschak E, Merk D. Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. ACS Pharmacol Transl Sci 2021;4:966-79. [PMID: 33860214 DOI: 10.1021/acsptsci.1c00041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 179-194 [PMID: 29375204 DOI: 10.3748/wjg.v24.i2.179] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 55] [Article Influence: 14.8] [Reference Citation Analysis]
27 Fang X, Du Z, Duan C, Zhan S, Wang T, Zhu M, Shi J, Meng J, Zhang X, Yang M, Zuo Y. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sci 2021;270:118966. [PMID: 33482185 DOI: 10.1016/j.lfs.2020.118966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Park JW, Kim SE, Lee NY, Kim JH, Jung JH, Jang MK, Park SH, Lee MS, Kim DJ, Kim HS, Suk KT. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. Int J Mol Sci 2021;23:426. [PMID: 35008852 DOI: 10.3390/ijms23010426] [Reference Citation Analysis]
29 Baandrup Kristiansen MN, Veidal SS, Christoffersen C, Feigh M, Vrang N, Roth JD, Erickson M, Adorini L, Jelsing J. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterol 2019;19:228. [PMID: 31883514 DOI: 10.1186/s12876-019-1149-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]